Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The ESC is proud to be able to recognise these exceptional cardiologists for their contribution to medicine and hope that by recognising them, they will be an inspiration to future generations.
This year, two ESC Gold Medallists receive ESC honours:
Dr. Bernard Gersh and Prof. Alain Cribier.
Dr. Gersh is Professor of Medicine at the Mayo Clinic College of Medicine having received his undergraduate degree at the University of Cape Town and obtaining a D.Phil at Oxford University. He also has an Honorary PhD from the University of Coimbra, Portugal. He has published approximately 880 manuscripts, 140 book chapters, and has edited 15 books. He has served on multiple editorial boards and is currently Deputy Editor of the European Heart Journal. Prior awards include the Silver Medal of the European Society of Cardiology, the James B. Herrick Award, the Distinguished Achievement Award of the American Heart Association, Master of the American College of Cardiology, and the Hatter Award for the Advancement of Cardiovascular Science from the University College London and the University of Cape Town. Dr. Gersh is the 2015 recipient of the Mayo Clinic Distinguished Alumni Award.
Prof. Alain Cribier, MD, has been for 20 years Chief of Cardiology at the University Hospital Charles Nicolle of Rouen, France. He became widely recognized for having developed new interventional technologies for the treatment of valvular heart diseases: Balloon Aortic Valvuloplasty in 1985, Mitral Commissurotomy in 1994, and after 15 years of research the Transcatheter Implantation of Aortic Valves (TAVI), performing the first world case in Rouen in 2002. This last breakthrough technology which is now widely used in the world with more than 300 000 patients treated and an explosive growth will have a durable impact on the pattern of medical practice. Prof Cribier has received a number of prestigious scientific distinctions and awards for his pioneering work. He has published more than 600 indexed articles in the fields of interventional cardiology, valve disease and innovative technologies.
This year, three ESC Gold Medallists receive ESC honours:
Professor Keith Fox, Professor Michel Haissaguerre and Professor Richard Popp
ESC: Professor Fox, you have a long association with the ESC. How did it all start?
KF: I was one of the founding Fellows of the ESC back in the 1990s and since then have been responsible for several studies in acute coronary syndromes and thrombosis, with key results incorporated into European guidelines. Some of our results from the GRACE study, for example, have provided strong evidence on risk assessment and its timing in acute coronary syndromes. At a more formal level I was a board member of the ESC from 2008 to 2010 and from 2012 to 2014, and also Chair of the Scientific & Clinical Programme Committee for the ESC. Last year there were more than 30,000 taking part and a record number of abstracts submitted. That’s plenty of work for the Programme Committee!
And your principal scientific and clinical interests?
Acute coronary diseases and atherothrombosis - in fact, the whole pathway from plaque formation to clinical manifestations. So this has involved me in studies of disease mechanisms in ACS to the assessment of antiplatelet and anticoagulant therapies. Presently, we are looking at the influence of genes and inflammation on plaque rupture events.
Which of these studies are you most proud of?
Well it’s difficult to say. They seem to have happened in a series of chapters, starting with our first studies on tPA in St Louis. But I guess I must be most proud of those whose outcomes have been implemented into guidelines and everyday practice in ACS. So to that extent I’d note our studies from the GRACE registry programme, and the RITA, ROCKET-AF and OASIS programmes. The RITA-3 trial in 2005, for example, compared a strategy of routine angiography and revascularisation in non-STE ACS patients with a non-intervention strategy of watchful management. There was uncertainty about this at the time, but our results over five years clearly showed the benefit of routine intervention. So now, for higher risk patients we adopt a routine strategy of early angiography and intervention. More recently we’ve updated the algorithms derived from the GRACE registry data into a simple web-based and app risk calculator. The original risk prediction model was based on outcomes from more than 100,000 ACS patients, and now the risk scores we calculated have been validated externally and prospectively.
What does an ESC gold medal mean to you?
Of course, I feel very honoured, but also a little embarrassed to be in such company. My contributions to cardiology and the ESC seem somewhat modest alongside those of other gold medallists, but it s a great honour and one that I feel very proud of and very grateful for.
ESC: How did you first become interested in cardiology?
MH: Initially, I decided to study medicine because I was interested in psychology. But during my second year internship with Professor Jean Francois Warin in Bordeaux I became fascinated by the way 12-lead ECG traces could describe an invisible electrical mechanism operating within the heart.
What have been your main research interests?
Once simple arrhythmias became, in the words of Douglas Zipes, ‘an endangered species’, the last big hurdle to overcome was cardiac fibrillation. My research team’s contribution has been to demonstrate that these chaotic wavelets have discrete origins, with the igniting sparks located mostly in the pulmonary veins in the atria or Purkinje cells in the ventricles.
How did radio ablation for atrial fibrillation come about?
With Pierre Jais, Mélèze Hocini, Dipen Shah and others I began mapping the first premature beat that initiates fibrillation. We found the sources of AF were not in the atria, but fired from cells in the pulmonary veins located in the vascular wall. It took about four years to be sure of our results – 99% perspiration for 1% inspiration. Now over 300,000 patients have been treated by targeting the pulmonary veins.
Have you done the same for VF?
The same mapping concept was performed for patients with repetitive VF, but proved challenging because of the rapid syncopal nature of VF and isolated runs of ventricular ectopies. We found Purkinje sources initiating VF in both normal hearts and nearly all types of cardiac disease, with confirmation by discrete successful ablation. Such findings could have large therapeutic implications.
What does your new institute hope to achieve?
In 2012 we established the LIRYC Electrophysiology and Heart Modelling Institute in Bordeaux to develop a multidisciplinary programme dedicated to cardiac electrical dysfunctions such as AF, ventricular tachyarrhythmias and electrical ventricular dyssynchrony leading to heart failure using high-resolution mapping, cardiac imaging, signal processing and computer modelling. The institute brings together over 150 practitioners with multiple specialties in electrophysiology - from ion channels to whole heart and patient care.
What are your future research goals?
While we’ve made progress in understanding arrhythmia mechanisms, the identification of risk factors, genetic abnormalities and tissue biomarkers needs to be improved. We need to be able to recognise those individuals who are susceptible to VF and sudden death. Advances will hopefully help optimise screening and therapeutic protocols and reduce the burden of arrhythmic morbidity and mortality.
ESC: What first attracted you to cardiology?
RLP: The cardiac physical exam was the most fascinating thing I could imagine - I had always wanted to understand how the heart worked both normally and under the influence of disease.
Who have been your most influential mentors and how did they help your career development?
J. Michael Criley from Johns Hopkins got me involved in angiography and Harvey Feigenbaum from Indiana University was one of the first in the US to use ultrasound for cardiac imaging. I’d also like to acknowledge over 150 dedicated cardiology fellows who taught me an enormous amount and pushed me to answer their challenging questions.
What do you regard as your greatest clinical and or scientific achievement?
I was privileged to be part of the development of virtually all aspects of ultrasound cardiac diagnosis. My work was developing non-invasive ways to measure left ventricular volume, stroke volume and ejection fraction - and establishing standards for examination and measurement methods in echocardiography. With Liv Hatle I helped develop Doppler methods to measure gradients across heart valves and methods to recognise diastolic ventricular dysfunction. But one of my greatest achievements has been my involvement in the careers of a large number of leading academic cardiologists including Fausto Pinto and Jos Roelandt.
What do you regard as the most significant development in your field of cardiology over the last 20 years?
The fact that non-invasive methods have replaced invasive cardiac catheterisation for assessing structural heart disease is a major advance for patients allowing serial monitoring of the natural course of valve disease and heart failure.
Looking into a crystal ball how do you see your field developing?
Use of personal hand-held inexpensive ultrasound imaging devices will have a big role to play in augmenting physical exams. I believe that hand-held ultrasound units, the size of a cell phone, will ultimately replace the stethoscope.
What advice would you give to young cardiologists?
Providing ‘patient centered care’ with a team of healthcare providers should be your focus. Training to do everything the team can provide will not serve either you or the patient well.
How have you achieved a work life balance?
I have been incredibly lucky to have a wonderful wife Janis, two sons and five grandchildren. While you can always get someone to cover your patients, no one else can cover your role as a spouse or parent.
Professor Sir Rory Collins
Professor Petr Widimský
Professor Alain Carpentier
Jean Claude Daubert
Frans Van de Werf
Pavel LUKLESC President 1968 – 1972
Herman SNELLENESC President 1972 – 1976
Henri DENOLINESC President 1976 – 1980
Franz LOOGENESC President 1980 – 1984
Paul HUGENHOLTZESC President 1984 – 1988
Hans-Peter KRAYENBÜHLESC President 1988 – 1990
Michel BERTRANDESC President 1991 – 1994
Sigurd NITTER-HAUGEChairman Executive Scientific Committee 1991 – 1994
Philip POOLE-WILSONESC President 1994 – 1996
Günter BREITHARDTESC President 1996 – 1998
AMERICAN COLLEGE OF CARDIOLOGY 1999
Wil NEIJMANN2000Sir Richard DOLL2000
Kalevi PYÖRÄLÄ 2000 Lars RYDÉNESC President 1998-2000
Henrick Joan Joost WELLENS2002
Attilio MASERI2002 Michiel J. JANSE2002 Editor in Chief Cardiovascular Research 1994 – 2002
Maarten L. SIMOONSESC President 2000-2002
Jean-Pierre BASSANDESC President 2002-2004
A John CAMM2005
Michal TENDERAESC President 2004-2006
Sir Magdi YACOUB2006